Abstract Purpose of Review This review offers a critical narrative evaluation of emerging
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …

Background Recent studies have shown that sodium-glucose cotransporter-2 inhibitors
(SGLT2i) can achieve significant improvement in blood pressure in people with diabetes …

Background Metabolic–bariatric surgery delivers substantial weight loss and can induce
remission or improvement of obesity-related risks and complications. However, more robust …

Objectives To assess the cardiovascular and renal efficacy and safety of sodium-glucose
cotransporter-2 (SGLT2) inhibitors in patients without diabetes. Methods We searched …

Na+-glucose cotransporter-2 (SGLT2) inhibitors are the new mainstay of treatment for
diabetes mellitus and cardiovascular diseases. Despite the remarkable benefits, the …

The prevention of cardiac life-threatening ventricular fibrillation and stroke-provoking atrial
fibrillation remains a serious global clinical issue, with ongoing need for novel approaches …

Background: Sodium–glucose cotransporter 2 (SGLT2), also known as solute carrier family
5 member 2 (SLC5A2), is a promising target for a new class of drugs primarily established …

Sodium-glucose cotransporter inhibitor/inhibition (SGLTi), initially approved as a glucose-
lowering therapy for type 2 diabetes, is associated with decreased risks for many of the most …

Sarcopenia, the age-related loss of muscle strength and mass or quality, is a common
condition with major adverse consequences. Although the pathophysiology is incompletely …

Despite the growing body of evidence regarding the beneficial cardiovascular effects of
sodium–glucose cotransporter‐2 (SGLT2) inhibitors, clinical data in individuals without …